Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 11/26 11:30:00 am
7785 GBX   -0.19%
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regimen
RE
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Explainer: When will COVID-19 vaccines be generally available in the United States?

10/16/2020 | 01:30pm EST
FILE PHOTO: A woman holds a small bottle labeled with a

(Reuters) - U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts.

Pfizer Inc said on Friday it could file for U.S. authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November, suggesting it is possible a vaccine could be available in the United States this year.

WHAT DOES IT MEAN FOR A VACCINE TO BE GENERALLY AVAILABLE?

General availability is when every American who wants the vaccine can get it. There are currently no COVID-19 vaccines approved by U.S. regulators, although a handful are in late-stage trials to prove they are safe and effective.

Experts estimate that at least 70% of roughly 330 million Americans would need to be immune through a vaccine or prior infection to achieve what is known as herd immunity, which occurs when enough people are immune to prevent the spread of the virus to those unable to get a vaccine.

HOW LONG BEFORE VACCINE PRODUCTION IS FULLY RAMPED UP?

The CDC anticipates that up to 700 million doses of vaccine will be available in April of 2021, enough to vaccinate all Americans because most vaccines in development require two doses per person.

It has forecast that 35 million to 45 million doses of vaccines will be available in the United States by the end of this year from the first two companies to receive authorization. The current front-runners are Pfizer and Moderna Inc.

Though 35 million to 45 million doses sounds like a lot, obtaining enough doses to inoculate everyone in the United States will likely take until later in 2021. CDC Director Robert Redfield told a congressional hearing in September that most Americans will be vaccinated by July, not April.

Drugmakers have been more ambitious with their calculations. Pfizer and BioNTech SE have said they expect to have 100 million doses available worldwide by the end of 2020, but did not specify how much of that was earmarked for the United States. Moderna has said it is on track to make around 20 million doses by the end of the year and between 500 million and 1 billion doses a year beginning in 2021.

AstraZeneca Plc has said it could deliver as many as 300 million doses of its experimental vaccine in the United States as early as October but its U.S. trial has been on hold since September.

WHO WOULD GET AN APPROVED VACCINE FIRST?

The CDC has said that if supplies are limited, the earliest inoculations may go to healthcare workers, people at increased risk for severe COVID-19, people aged 65 years and older and essential workers.

It is unclear when a vaccine will be available for children as major drugmakers have yet to include them in late-stage trials. Pfizer and BioNTech have approval from regulators to start recruiting volunteers as young as 12 for vaccine studies.

WHICH COMPANIES WILL LIKELY ROLL OUT A VACCINE QUICKLY?

Pfizer/BioNTech said it may have data as early as October and Moderna says it could have similar evidence in November. The vaccines would first need to be approved or authorized for emergency use by U.S. regulators, and Pfizer says it expects to have the safety data it needs in the third week of November to file with the U.S. Food and Drug Administration.

Drugmakers have already started manufacturing supplies of their vaccine candidates to be ready as soon as they get the go-ahead. The U.S. Department of Defense and the CDC plan to start distribution of vaccines within 24 hours of regulatory authorization.

Several drugmakers including Pfizer, AstraZeneca, Johnson & Johnson and Novavax Inc have said they expect to produce at least 1 billion doses of their vaccines next year if they get regulatory authorization.

Sanofi SA and GlaxoSmithKline Plc are also working on developing a vaccine they say could be authorized next year.

(Reporting by Carl O'Donnell, Michael Erman and Caroline Humer in New York; Editing by Bill Berkrot and Matthew Lewis)

By Carl O'Donnell and Michael Erman


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.67% 7748 Delayed Quote.1.85%
BIONTECH SE 3.03% 104.96 Delayed Quote.209.80%
GLAXOSMITHKLINE PLC 0.83% 1390 Delayed Quote.-21.87%
MODERNA, INC. 10.78% 109.18 Delayed Quote.458.18%
NOVAVAX, INC. 7.63% 102.6 Delayed Quote.2,477.89%
PFIZER INC. -0.19% 36.53 Delayed Quote.-1.59%
SANOFI 1.37% 85.37 Real-time Quote.-4.74%
All news about ASTRAZENECA PLC
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regime..
RE
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
02:11pRussia's Sputnik V developers call on AstraZeneca to try combining vaccines
RE
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
11:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
10:58aANALYSIS : Questions over AstraZeneca's COVID-19 vaccine data risk delaying appr..
RE
10:06aWhy the Oxford Astrazeneca Vaccine Is Now a Global Gamechanger
AQ
09:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
09:02a'WE'RE READY' : Schiphol airport gears up for chilled vaccine cargos
RE
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 46,6x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,48 $
Last Close Price 103,46 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC1.85%137 013
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-4.41%282 585
PFIZER INC.-1.59%203 048
NOVARTIS AG-11.88%202 620
MERCK & CO., INC.-11.97%202 555